Analysis of key points in medication guidance for Elacetrant

Elacestrant (Elacestrant) is an oral selective estrogen receptor degrader (SERD), mainly used to treat hormone receptor-positive, HER2-negative breast cancer. It blocks estrogen-driven tumor growth by specifically binding to the estrogen receptor (ER), promoting receptor degradation and inhibiting the ER-mediated signaling pathway. Compared with traditional estrogen receptor antagonists, elastran is more comprehensive in degrading receptors and inhibiting signaling pathways, and it also has certain efficacy in drug-resistant patients.

Elagrastrant is mainly used for ER positive, HER2 negative breast cancer patients who have received endocrine therapy but are resistant to it. Patients need to use it under the guidance of a doctor, usually in combination with other endocrine or targeted treatment options to delay tumor progression. The drug is suitable for oral use and is convenient for patients to self-administer in outpatient clinics. However, caution is required for patients with abnormal liver and kidney function, and the dose may need to be adjusted.

The standard dose is taken orally once a day. It is recommended to take it at a fixed time. It can be taken on an empty stomach or with food. However, avoid taking foods or drugs that affect drug metabolism at the same time, such as grapefruit. Patients should strictly follow the doctor's instructions and should not increase or decrease the dose or interrupt treatment on their own to avoid insufficient blood concentration or increased risk of drug resistance. At the same time, blood routine, liver function and imaging evaluation need to be reviewed regularly during the medication period to monitor the efficacy and safety.

Common side effects include hot flashes, fatigue, nausea, musculoskeletal pain, and mild gastrointestinal discomfort. Some patients may have elevated liver function indicators or prolonged QT interval, so liver function and electrocardiogram need to be monitored regularly. When obvious discomfort occurs, the doctor should be informed in time, and the doctor will judge whether to adjust the dose or take symptomatic treatment measures. Through standardized medication, regular follow-up and lifestyle management, the best clinical efficacy of elastran can be achieved while ensuring safety.

Reference link:https://www.drugs.com